

I hereby certify that this correspondence is being filed via  
EFS-Web with the United States Patent and Trademark Office  
on JULY 26, 2007

PATENT  
Attorney Docket No.: 016930-000816US  
Client Reference No.: CJ01656KQ

TOWNSEND and TOWNSEND and CREW LLP

By: Kimberly Rava

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

Heidrun Engler et al.

Application No.: 10/055,863

Filed: January 22, 2002

For: COMPOSITIONS AND METHODS  
FOR ENHANCING DELIVERY OF  
THERAPEUTIC AGENTS TO CELLS

Confirmation No.: 4929

Examiner: Elli Peselev

Art Unit: 1623

SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT UNDER  
37 CFR §1.97 and §1.98

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. Copies of references 0003 through 0011 [in compliance with the requirements of 37 CFR §1.98(a)(2)] are enclosed.

It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR §1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no

representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

This IDS is being filed before the mailing date of the final Office Action or Notice of Allowance.

Please charge the IDS fee of \$180 to Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Frank J. Mycroft  
Reg. No. 46,946

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, Eighth Floor  
San Francisco, California 94111-3834  
Tel: 925-472-5000  
Fax: 925-472-8895  
FJM:kar

Substitute for form 1449A&B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/055,863
				Filing Date	January 22, 2002
				First Named Inventor	Engler, Heidrun
				Art Unit	1623
				Examiner Name	Elli Peselev
Sheet	1	of	2	Attorney Docket Number	016930-000816US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code <sup>2</sup> (if known)			
	0001	US-6,013,638	01-11-2000	Crystal et al.	
	0002	US-7,163,925 B1	01-16-2007	Jin et al.	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
	0003	BENEDICT, William F. et al., "Intravesical Ad-IFN $\alpha$ Causes Marked Regression of Human Bladder Cancer Growing Orthotopically in Nude Mice and Overcomes Resistance to IFN $\alpha$ Protein," <i>Molecular Therapy</i> , 10(3):525-532 (September 2004)	<input type="checkbox"/>	
	0004	HJELMELAND, Leonard M. et al., "A New Class of Nonionic Detergents with a Gluconamide Polar Group," <i>Analytical Biochemistry</i> 130:485-490 (1983)	<input type="checkbox"/>	
	0005	HORTON, Holly M. et al., "Antitumor Effects of Interferon- $\omega$ : In Vivo Therapy of Human Tumor Xenografts in Nude Mice," <i>Cancer Res.</i> 59:4064-4068 (August 15, 1999)	<input type="checkbox"/>	
	0006	IZAWA, Jonathan I. et al., "Inhibition of Tumorigenicity and Metastasis of Human Bladder Cancer Growing in Athymic Mice by Interferon- $\beta$ Gene Therapy Results Partially from Various Antiangiogenic Effects Including Endothelial Cell Apoptosis <sup>1</sup> ," <i>Clin. Cancer Res.</i> 8(4): 1258-1270 (2002)	<input type="checkbox"/>	
	0007	KOSHIDA, Kiyoshi et al., "Prospects for Molecular Research in Urological Oncology: Bladder Cancer," <i>Hinyokika kiyo. Acta Urologica Japonica</i> 47(1):815-818 (2001)	<input type="checkbox"/>	
	0008	KUBALL, Jürgen et al., "Successful Adenovirus-Mediated Wild-Type p53 Gene Transfer in Patients With Bladder Cancer by Intravesical Vector Instillation," <i>J. Clin. Onc.</i> 20(4):957-965 (February 15, 2002)	<input type="checkbox"/>	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/055,863
				Filing Date	January 22, 2002
				First Named Inventor	Engler, Heidrun
				Art Unit	1623
				Examiner Name	Elli Peselev
Sheet	2	of	2	Attorney Docket Number	016930-000816US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
	0009	LIN, Lee-Fong et al., "A System for the Enhancement of Adenovirus Mediated Gene Transfer to Uro-Epithelium," <i>J. Urol.</i> 168:813-818 (August 2002)	<input type="checkbox"/>	
	0010	SHIAU, Ai-Li et al., "Postoperative Immuno-Gene Therapy of Murine Bladder Tumor by <i>In Vivo</i> administration of retroviruses expressing mouse interferon- $\gamma$ ," <i>Cancer Gene Therapy</i> 8(1):73-81 (2001)	<input type="checkbox"/>	
	0011	SUTTON, Mark A. et al., " <i>In Vivo</i> Adenovirus-Mediated Suicide Gene Therapy of Orthotopic Bladder Cancer," <i>Mol. Ter.</i> 2(3):211-217 (September 2000)	<input type="checkbox"/>	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.